HanAll Biopharma saw the highest growth of 299% in patent filings in December and 99% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 66% and grants by 99%. GlobalData’s DataBook provides a comprehensive analysis of HanAll Biopharma‘s patent filings and grants. Buy the databook here.
HanAll Biopharma has been focused on protecting inventions in European Patent Office(EPO) with five publications in Q4 2023
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 50% filings and 33% grants. The European Patent Office(EPO), China(CN), World Intellectual Property Organization(WIPO), and Germany(DE) patent Office are among the top ten patent offices where HanAll Biopharma is filings its patents. Among the top granted patent authorities, HanAll Biopharma has 33% of its grants in European Patent Office(EPO), 33% in Germany(DE) and 33% in Japan(JP).
Amgen and Johnson & Johnson could be the strongest competitors for HanAll Biopharma
Patents related to rare diseases lead HanAll Biopharma's portfolio
HanAll Biopharma has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q4 2023.
Multiple sclerosis related patents lead HanAll Biopharma portfolio followed by autoimmune encephalitis (post-infectious), and pemphigus vulgaris
HanAll Biopharma has highest number of patents in multiple sclerosis followed by autoimmune encephalitis (post-infectious), pemphigus vulgaris, pemphigus, and myasthenia gravis.
For comprehensive analysis of HanAll Biopharma's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.